# Dose-response Study of OPC-12759 Ophthalmic Suspension

> **NCT00234078** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 290 (actual)

## Conditions studied

- Dry Eye Syndromes

## Interventions

- **DRUG:** 0.5% OPC-12759
- **DRUG:** 1% OPC-12759
- **DRUG:** 2% OPC-12759
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00234078
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-04
- **Final completion:** 2007-03
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2014-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234078, "Dose-response Study of OPC-12759 Ophthalmic Suspension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00234078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*